BHC
Bausch Health Cos., Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$6.32
+0.32%Oct 12, 2026, 12:00 UTC
Bausch Health Companies Inc. and its gastroenterology business, Bausch Health Companies Inc., announced results from a multicenter pilot study reporting improved adherence to evidence-based cirrhosis monitoring and treatment practices in community gastroenterology settings.
Source:Oct 12, 2026, 10:45 UTC
Bausch + Lomb Corporation appointed Thomas J. Appio as interim chief executive officer, effective immediately; he will continue as CEO of Bausch Health Companies Inc..
Source:Oct 6, 2026, 11:00 UTC
Bausch Health Companies Inc. announced it will release its third quarter 2026 financial results after market close on October 28, 2026, followed by a conference call and webcast.
Source:Sep 23, 2026, 20:00 UTC
A federal judge in Connecticut granted preliminary approval to a distribution plan for a $96.5 million multi-state settlement resolving allegations that generic drug manufacturers conspired to inflate prices, opening the claims process for consumers who bought eligible drugs between May 2009 and December 2019.
Source:Sep 10, 2026, 12:12 UTC
SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.
Source:Sep 8, 2026, 12:00 UTC
Bausch Health and YUN announced an expansion of their collaboration to bring microbiome-friendly skincare products to Mexico and additional EMEA markets, including the Czech Republic, Slovakia, Ukraine, Bulgaria, and Kazakhstan.
Source:Aug 12, 2026, 22:30 UTC
Bausch Health Companies Inc. reported Q2 2026 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and improved margins and cash flow.
Source:Aug 6, 2026, 11:04 UTC
Thomas J. Appio, CEO of Bausch Health, was appointed to the board of directors of Bausch + Lomb Corporation, effective August 5, 2026.
Source:Jul 29, 2026, 20:05 UTC
Bausch Health Companies Inc. announced its second quarter 2026 financial results on July 29, 2026.